After Major Setback, GSK/Sanofi Vaccine Will Be Delayed To End Of ’21
The vaccine failed to trigger the desired immune response in people ages 50 and older, forcing the company to rethink its antigen formulation. The news is a blow for many governments who had ordered millions of doses of the shot, including the United States.